Natalie Filmann
0000-0003-0424-2317
Publication & Citation Trends
Publications
0 total
Abstract RF2-01: Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) - a Pooled Analysis from nine Neoadjuvant GBG/AGO-B Trials
Cited by 0
Semantic Scholar
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
Cited by 0
Semantic Scholar
352P Long-term survival of HER2-positive breast cancer patients with brain metastases: Final analysis of the Brain Metastases in Breast Cancer Registry (BMBC)
Cited by 0
Semantic Scholar
585P HER2 IHC status of primary breast cancer tumor and brain metastases in the BMBC registry
Cited by 0
Semantic Scholar
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) OA
Cited by 5
Semantic Scholar
RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
Cited by 2
Semantic Scholar
Abstract PS14-07: Exploring Circulating Leukocyte RNA Expression: Implications for Treatment Outcomes and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Enrolled in the GeparNuevo Trial
Cited by 0
Semantic Scholar
266P Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial
Cited by 0
Semantic Scholar
Research Topics
Gallbladder and Bile Duct Disorders
(23)
Liver Disease Diagnosis and Treatment
(16)
Hepatitis C virus research
(15)
Hepatitis B Virus Studies
(12)
Esophageal and GI Pathology
(12)
Affiliations
Goethe University Frankfurt
Dalhousie University
Apple (Israel)
Goethe Institute
Bechtel (United States)